What is the impact of bridging therapy on the outcomes of patients receiving CAR T therapy?

L: English

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Michael Jain, Moffitt Cancer Center, Tampa, US. We asked: What is the impact of bridging therapy on the outcomes of patients receiving CAR T therapy?

Michal Jain talks about the rationale behind the study looking to improve outcomes for patients with relapsed or refractory lymphoma undergoing CAR T cell therapy by using bridging therapy. He also summarises the study results.